

## BEST AVAILABLE COPY

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
23 August 2001 (23.08.2001)

PCT

(10) International Publication Number  
**WO 01/61037 A1**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/68**,  
G01N 33/536

(21) International Application Number: PCT/SE01/00341

(22) International Filing Date: 16 February 2001 (16.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0000538-9 18 February 2000 (18.02.2000) SE

(71) Applicants and

(72) Inventors: LANDEGREN, Ulf [SE/SE]; Eksoppsvägen  
16, S-756 43 Uppsala (SE). FREDRIKSSON, Simon  
[SE/SE]; Salagatan 13B, S-753 30 Uppsala (SE).

(74) Agent: ALDENBÄCK, Ulla; Dr Ludwig Brann Patent-  
byrå AB, Box 1344, S-751 43 Uppsala (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AT  
(utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA,

CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility  
model), DK, DK (utility model), DM, DZ, EE, EE (utility  
model), ES, FI, FI (utility model), GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK  
(utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.



WO 01/61037 A1

(54) Title: METHODS AND KITS FOR PROXIMITY PROBING

(57) Abstract: The present invention relates to sensitive, rapid and convenient assays for detection and/or quantification of one or several analyte(s) in solution using so called proximity probes. The proximity probes comprise a binding moiety and a nucleic acid. The nucleic acid from one proximity probe is only capable of interaction with the nucleic acid from the other proximity probe when these are in close proximity, i.e. have bound to the analytes for which they are specific. The present invention relates to methods and kits for proximity probing and are performed in solution without the need of a solid phase.

B4

WO 01/61037

PCT/SE01/00341

1

**METHODS AND KITS FOR PROXIMITY PROBING****Field of the invention**

The present invention is within the medical field. More precisely, the invention relates to sensitive, rapid and convenient assays for detection and/or quantification of one or several analytes in solution using so called proximity probes.

**Background of the invention**

Most protein detection assays rely on the efficient separation of target bound detector reagents from non-bound reagents. The assay sensitivity is crucially dependent on this separation and the power of the reporter system used. For the separation, a solid phase is usually employed containing an immobilised affinity reagent for the analyte with a secondary affinity reagent for the detection, as in a sandwich ELISA. In the operation of washing off unbound detector reagents the stringency must be carefully balanced. At high stringency of washing the background is lower at the cost of reduced detection signal of analytes and at low stringency the probability of detection is higher, but at the cost of higher background.

Assays that use a solid phase require considerable time and effort for the analysis. The binding of reagents and analytes to the surface is a time consuming process and the washing steps must be precisely and reproducibly controlled between samples to give exact results. Solid phase assays are also more difficult to automate than homogenous assays.

Assays that do not require a solid phase and the associated washing steps have important advantages. Such homogenous assays exist, for example the scintillation proximity assay (1) and assays based on fluorescence resonance energy transfer (2, 3). However these assays suffer from a low sensitivity due to poor signal to noise ratios.

In W0 97/00446 an ultrasensitive immunoassay and kit is described using two reagents that are crosslinked if they adhere to an analyte. The coincident binding of two analytes give rise to an interaction product, which may be selected so that it can

WO 01/61037

2

PCT/SE01/00341

serve as a template in amplification reactions, increasing specificity through the requirement for dual recognition and reducing the risk for non-specific signals. This immunoassay is performed on a solid support.

**Summary of the invention**

This invention is characterised by its ability to detect and quantify one or several analytes in solution in a homogenous one tube assay with high sensitivity and specificity. So called, proximity-probes comprising a binding moiety with affinity for the analyte and also a reactive functionality, are added to the sample solution. These probes are then permitted to interact with one another and will do so to a greater extent if two or more proximity-probes have bound the same individual analyte molecule. Since the proximity-probes are capable of binding the analyte at multiple sites, the analyte acts in a way analogous to a catalyst by bringing the reactive probes closer to one another and increasing their ability to interact through an increased local concentration. The interaction between the coupled functionalities results in a detectable signal in a secondary reaction.

In the standard procedure for the method, the analytes may be proteins, nucleic acids or any other molecule of interest capable of specifically binding two or more proximity-probes. One or more analyte(s) may be detected/quantified. Also aggregations of one analyte into a multimeric complex consisting of one protein or peptide type may be detected/quantified as well as complexes of two or more different molecules close to each other.

Complexes of different proteins can also be detected by the assay. In such a case, the proximity-probes bind to two different proteins, but gain proximity if these two proteins are close to each other.

Several neurological disorders are caused by the formation of protein aggregates, so called amyloid plaques. Alzheimer's disease, Parkinson's disease, Creutzfeldt-Jakob's disease, motor neuron disease, and Huntington's disease, are some examples (4). As these diseases progress, more and more aggregates form. If these aggregates could be

WO 01/61037

PCT/SE01/00341

3

detected at an early stage of the disease, proper medical attention could be given to the patient. Detecting the existence of prion proteins, which cause scrapie, is another example of aggregate forming proteins (5). These aggregates are ideal analytical targets for proximity-probing. Since an aggregate contains many copies of the same protein, a proximity-probe specific for this protein would bind at multiple sites along the aggregate. These proximity-probes will thereby gain proximity upon binding the aggregate. The high sensitivity of proximity-probing could detect such aggregate formation at an early disease stage. The invention also relates to detection/quantification of protein aggregates comprising proteins of different types, such as antibodies and antigens. The existence of infectious prion protein aggregates in food is also of great importance. This is expected to be of great importance for detection/quantification according to the invention of infectious agents causing BSE (bovine spongiform encephalitis) and the human counterpart CJD (Creutzfeldt-Jacobs disease).

The binding moieties of the proximity-probes may be proteins such as monoclonal and polyclonal antibodies, peptides, lectins, nucleic acids, carbohydrates, soluble cell surface receptors, combinatorially derived protein from phage display or ribosome display, or any other type of binding moiety. Combinations of binding moieties may also be used.

The reactive functionality of a proximity-probe is comprised of a nucleic acid coupled to the binding moiety. This coupling may be a covalent crosslinking or non-covalent, as can be exemplified in a streptavidin-biotin coupling. As proximity-probes are brought near each other, for example when pair wise bound to the target analyte, the coupled nucleic acids are also brought in vicinity of each other. The proximity of these target bound nucleic acids is used to promote various detectable interactions between these nucleic acids. This nucleic acid interaction is detected in a secondary step of the analysis. In most cases the secondary detection of the amount of nucleic acid interaction will involve a specific amplification of the interaction product.

WO 01/61037

PCT/SE01/00341

4

In the case of two proximity probes, one of the binding moieties will typically have a certain nucleic acid sequence coupled to it by its 5' end while the other binding moiety has a nucleic acid sequence coupled to it by its 3' end. The 5' proximity-probe thus has a free 3' hydroxyl capable of reacting with the 5' phosphate of the second binding moiety through interaction.

The reactive functionalities (nucleic acids) present on these binding moieties are capable of pair wise reacting when present at a high concentration. In the detection procedure the proximity-probes are added to a sample at a low concentration. The concentration of the proximity-probe is set so low that the proximity-probes will not react with each other to any great extent when the proximity-probes are not near each other. But when two or more the proximity-probes bind to the analyte the high local concentration promotes interaction between the probes, resulting in a detection signal exceeding the analyte independent background signal.

The product of the ligation reaction will in most cases exist at a very low concentration in need of an amplification step in order to detect it. The resulting ligation between these nucleic acids is readily amplifiable by several reactions, such as polymerase chain reaction (PCR), strand displacement amplification (6), NASBA (7), RNA transcription (8), invader assay (9). These amplification reactions are thus designed only to give a product when the two nucleic acids have been crosslinked by ligation. This is done by placing the primers for PCR or SDA, one on each conjugated nucleic acid. The amplification reaction can be followed in real-time by sequence specific TaqMan probes (10) or molecular beacons probes (11) or by using non-sequence specific intercalating fluorescent dyes such as SYBR green (12). The resulting product can also be quantified by electrophoresis in gels.

In some cases, a lot of ligation product is produced. It can then be directly analysed without the need of an amplification. Several methods can then be employed. For example, the first of the two united nucleic acid sequences can be designed to contain a sequence capable of binding through hybridisation to an immobilised oligonucleotide probe. Upon binding the oligonucleotide probe, the second nucleic acid sequence will also bind since the two are now linked by the ligation. All non bound sequences can be

WO 01/61037

PCT/SE01/00341

5

washed off and a labelled hybridisation probe specific for the second sequence will bind and detect the ligation product.

The two united nucleic acids may be analysed in a hybridisation based assay where the united sequence elements bind cooperatively and thereby much stronger than non united ones to an oligonucleotide probe. Such probes may be constructed in DNA microarrays to selectively bind nucleic acids with united sequence elements (13).

Thus, in a first aspect the invention relates to a method for detecting and/or quantifying one or more analyte(s) in solution, characterised by

- a) binding of two or more proximity probes to a respective binding site on said analyte(s), wherein the proximity probes are comprised of a binding moiety and a thereto coupled (conjugated or via linkage, such as a biotin-streptavidin linkage) nucleic acid, also sometimes referred to as a reactive functionality;
- b) allowing the binding moiety to bind to the analyte(s) and allowing the nucleic acids to interact with each other if they are in close proximity to each other; and c) detection and/or quantification of the degree of interaction between the nucleic acids with the proviso that binding moieties and the analyte(s) not all comprise nucleic acid.

In a second aspect, the invention relates to a kit for detecting and quantifying one or more analyte(s) in solution, comprising

- a pair of proximity probes comprising binding moieties with affinity for the analyte(s) and each provided with a nucleic acid (reactive functionality) capable of interacting with each other. In a preferred embodiment, one nucleic acid has a free 3' end and the other has a free 5' end.

The following components can optionally be added in the kit:

- a ligase and a splint template for joining the nucleic acids; and
- primers which hybridise to each of the nucleic acids.

In further aspects, the invention relates to use of the method and/or the kit according to the invention for the following purposes:

- for screening for ligand-receptor interaction antagonists a high throughput screening

WO 01/61037

PCT/SE01/00341

6

procedure;

- for competitive detection and/or quantifying of an unknown analyte in solution;
- for screening ligand candidates in a large pool;
- for screening of drug candidates from large libraries;
- for detection of infectious agents.

In a further aspect, the invention relates to a method for screening for ligand-receptor interaction antagonists, characterised by

- reacting two proximity probes having
  - a) a binding moiety with affinity for the receptor ligand and
  - b) a thereto bound (conjugated or via linkage, such as a biotin-streptavidin linkage) nucleic acid

with the receptor-ligand and its receptor and samples of potential ligand receptor interaction antagonists in a high throughput screening procedure; wherein a positive signal is generated when an antagonist is present.

Another aspect of the invention relates to a method for detecting and quantifying an unknown analyte in solution, characterised by

- reacting a proximity probe comprising
    - a) a binding moiety with affinity for the analyte and
    - b) a thereto bound nucleic acid
- with an analyte with thereto bound nucleic acid in the solution containing the unknown analyte;
- allowing the analyte with thereto bound nucleic acid to compete with the unknown analyte for binding to the binding moiety;
  - allowing the nucleic acids to bind to each other; and
  - detection and quantification of the amount of binding events between the nucleic acids, wherein the signal from the reaction is inversely proportional to the concentration of the unknown analyte.

Yet a further aspect of the invention relates to a method for detecting and quantifying an unknown analyte in solution, characterised by

WO 01/61037

PCT/SE01/00341

7

- reacting a receptor coupled to a nucleic acid (reactive functionality) with its receptor-ligand coupled to a nucleic acid (reactive functionality);
- allowing the nucleic acids to interact with each other;
- detection and/or quantification of the degree of interaction between the nucleic acids, wherein the detection signal will be decreased if a molecule blocking the receptor ligand complex is present.

**Choice of ligase enzymes and templates**

The ligation reaction is dependent on a hybridised template strand (also called DNA splint or splint template) when using a DNA ligase enzyme such as T4 DNA ligase. The two oligonucleotides to be ligated must hybridize to the template with the 3' end of one oligonucleotide lined up to the 5' phosphate of the other.

When the ligation template is added to the reaction it may hybridise to a pair of nearby proximity-probes and promote ligation. But if each proximity-probe oligonucleotide has bound a ligation template no ligation will occur since no single ligation template spans pairs of ligatable ends. If the ligation template is added at a high concentration the probability for a one to one hybridisation will be greater. But if the proximity-probes have bound their target, the high local concentration of their oligonucleotides will favour a generation of appropriate ligation substrates. This mechanism serves to promote ligation in the presence of analyte, and to inactivate proximity-probes in the absence of antigens, improving the signal to noise ratio.

The template should be designed so as to not give rise to any false amplification products. If incorrectly designed the ligation template may be used by the amplification enzyme, such as DNA polymerase, as a template for polymerisation. This extension, templated by the ligation template, may give rise to false products. To overcome this problem, DNA oligonucleotides may be ligated with an RNA oligonucleotide as template using the T4 DNA ligase enzyme. Taq DNA polymerase can not use RNA as a template for polymerisation, hence no false PCR products can arise from polymerisation on such a ligation template. A DNA splint with 2 short hybridisation regions (such as 10+10) also works like the RNA splint. But since the hybridisation is weak they will not template polymerisation at the high temperature of the PCR, due to the low melting temperature.



WO 01/61037

PCT/SE01/00341

8

Alternative means to react the conjugated oligonucleotides is through the T4 RNA ligase which does not need any template strand, or to use chemical ligation to join ends that cannot prime polymerisation reactions.

**Competitive dummy probes**

The background signal arising from ligated proximity-probe oligonucleotides which have not bound the target may be decreased by adding a dummy oligonucleotide. This oligonucleotide shall have the ability to ligate to either oligonucleotide conjugated to the target binding moiety through the same ligation template used in the regular ligation. However a ligation between this dummy oligonucleotide and the proximity-probe oligonucleotides will not give rise to any PCR reaction since the dummy oligonucleotide is designed to not contain the primer site required for PCR. The concentration of the dummy oligonucleotide is optimised to where it will readily ligate with the non-target bound proximity-probe oligonucleotides, but not compete in ligation with the target bound proximity-probes due to their high local concentration.

**Preincubation, followed by dilution and ligation for low affinity ligands**

In the case of detecting a target with proximity-probes of low affinity and slow binding kinetics a preincubation with the proximity-probes at a sufficiently high concentration for most analytes to be bound by probes is preferred. This preincubation is then quickly diluted in a large volume of cold buffer, and a portion of this dilution is subsequently added to a ligation reaction mixture. This ligation reaction mixture contains the template, ATP and ligase enzyme. The ligation mix may also contain the detection components as described above. The low temperature will minimise the dissociation of existing proximity-probe-target complexes while the vast dilution, will result in a decrease of the concentration of the proximity-probe oligonucleotides thereby lowering their reactivity and minimising the background signal. The dilution will also to a lesser extent decrease the true positive signal.

**Blocking probes for complex samples and sample dilution**

Samples of a high complexity, such as serum samples, contain many proteins other than the analyte of interest. When using DNA aptamers this causes a problem since

WO 01/61037

PCT/SE01/00341

9

they may unspecifically bind to other proteins in the solution besides the analyte. The assay should use as little probe as possible in order not to increase the background, so if the sample is complex the signal from analyte bound probes may decrease and the background increase due to the need to supply more probes. This can be overcome by adding a blocking molecule that will block out unspecific interactions by the analyte specific probes. Such a molecule may be an aptamer which resembles the specific one but does not have any high affinity for the analyte, or the ligatable ends.

Another way to overcome this problem is by diluting the complex sample prior to the analysis. This will greatly decrease the amount of proteins the probes may bind unspecifically to and thereby one can use a lower concentration of probes. The analyte will in this case also be diluted, but the high sensitivity of the proximity probing will still give a good detection and quantification.

#### **Detailed description of the invention**

There are several ways in which the oligonucleotides coupled to the binding moieties may interact when in proximity, figures 1-8 represent some examples. These interaction examples can also be used in combinations. Ligation reactions are not limited to enzymatically catalysed ligation but can be performed by chemical ligation, or catalysed by catalytic RNA or DNA.

Figure 1 explains the symbols used.

Figure 2 a) represents the hybridisation of a template oligonucleotide for ligation of proximity-probe oligonucleotides. This ligation can be detected via amplification by placing PCR primers, one on each proximity-probe oligonucleotide.

Figure 2b) Shows an additional oligonucleotide ligated in-between the proximity-probe oligonucleotides.

Figure 3) Shows a DNA polymerase catalysed "fill-in" reaction primed by a proximity-probe oligonucleotide, followed by ligation of the proximity-probe pair.

WO 01/61037

PCT/SE01/00341

10

Figure 4) Shows the use of a first hybridisation oligonucleotide (z) which binds to both proximity-probe oligonucleotides. Two other oligonucleotides (x and y) hybridise one to each proximity-probe-oligonucleotide and ligate forming an x-z-y oligonucleotide which is specifically detected. When the proximity-probes are not near each other, one oligonucleotide z will hybridise to all proximity-probe oligonucleotides. This disables the formation of any x-z-y ligation product, only forming x-z and z-y.

Figure 5) Generation of circular DNA (ligated padlock probe)(15), by ligation of two oligonucleotides, templated by the proximity-probe oligonucleotides. The circular DNA may be amplified by rolling circle amplification(14).

Figure 6) Ligation of one oligonucleotide, templated by hybridising to one proximity-probe oligonucleotide, resulting in a circle (ligated padlock probe). The circular DNA is readily primed for rolling circle amplification when the second proximity-probe oligonucleotide is proximity of the formed circle. The proximity is provided by target binding.

Figure 7) Shows the ligation of two proximity-probe oligonucleotides without the requirement of a hybridised template. T4 RNA ligase can catalyse a non templated ligation, and does so preferentially when the proximity-probe oligonucleotides are near each other.

Figure 8) Shows priming and templating of DNA polymerisation by the proximity-probes. The two proximity-probe oligonucleotides are weakly hybridised to each other and this hybridisation is stabilised cooperatively by analyte binding. This hybridisation and subsequent polymerisation reaction is optimised to occur preferentially when the proximity-probes are in proximity

Figure 9) Shows the ligation of three proximity-probes bound to the same analyte, requiring two ligation events for signal. The proximity-probe oligonucleotides are ligated and primer sites for amplification are placed to span over all three oligonucleotides.

WO 01/61037

PCT/SE01/00341

11

Fig 10 is a schematic drawing of PDGF-BB bound by two aptamer based proximity-probes, A1c and A2c. The aptamer sequence which binds PDGF-BB is shown in close to the protein. The TaqMan probe sequence used in PCR detection is shown. The ligation junction between the proximity-probes is marked with a line between the 3' end of A1c and the 5' end of A2c. The primer sites are boxed.

Fig 11. Results of proximity-probing of PDGF-BB using separate ligation and amplification/detection mixes. 1 uL of sample from a dilution series was analysed. The amount of ligation was quantified by the 5' exonuclease TaqMan PCR assay. A high Ct value corresponds to a low amount of ligation generated PCR templates.

Fig 12. Results of proximity-probing of PDGF-BB using a combined ligation and amplification mix, 1 uL of sample was analysed. A high Ct-value corresponds to a low amount of ligation generated PCR templates.

Fig 13. Example of universal proximity-probes, based on antibodies capable of binding to several primary antibody types.

Fig 14. Example of a proximity-probe pair used in a multiplex analysis. A positive signal is generated when the two matching sequence identification tags (ID:A and ID:B) are united. Two PCR primers are shown, one containing a biotin residue for making the product single stranded prior to DNA microarray hybridisation, and the other with a fluorescence marker for detection.

### **Example 1**

#### **PDGF detection using SELEX derived aptamers**

An example of proximity probing is an assay capable of the detecting platelet derived growth factor BB (PDGF BB). In this case the binding moieties which bind the protein at two sites are Selex (Systematic evolution of ligands by exponential enrichment)-derived aptamers (16). These are single stranded oligonucleotides selected repeatedly from very large random combinatorial libraries for affinity towards a target protein, in this case the B-chain of PDGF (17). The aptamer sequences are easily extended to

WO 01/61037

PCT/SE01/00341

12

contain an additional polynucleotide sequence besides the binding moiety. This extension contains the reactive functionality mentioned above. One aptamer has a 5' extension ending in a 5' phosphate group and the other aptamer has a 3' extension ending in a 3' hydroxyl. These two extensions may be united through a ligation reaction if they are hybridised to a template strand (figure 10).

The efficiency of such a ligation reaction is dependent on the concentration of the two proximity-probes. If these are in low concentration the reaction efficiency may be greatly increased by the presence of a molecule (analyte) capable of binding the two proximity-probes together, thus increasing their local concentration and promoting the reaction between the reactive functionalities or extensions. PDGF acts as such a "catalyst" by bringing together two aptamers with 3' or 5' extensions respectively. If the proximity-probes are added at a concentration of 5 pM the increase in effective concentration is estimated at 15 million times when the proximity-probes have bound PDGF.

The amount of PDGF present in the sample is proportional to the threshold cycle value (Ct-value) of the TaqMan assay, used in the course of a PCR reaction. Since PDGF BB is a homodimer the same binding moiety (selex aptamer) can be used for both proximity-probes. Statistically, half of the two probe/one PDGF complexes will be of the 3'-probe/PDGF/5'-probe type, while the 3'-probe/PDGF/3'-probe and 5'-probe/PDGF/5'-probe complexes will not result in any detectable signal.

#### Experimental procedure for proximity-probing of PDGF BB

To analyse several samples, three stock mixes of reagents are prepared. The first mix is the incubation mix with which the unknown sample is incubated for 1 to 2 hours at room temperature. This mix includes the two proximity-probes (selex aptamer and ligatable sequence). After the incubation, the ligation mix is added for five minutes at room temperature. This mix contains the ligase enzyme, a ligation template, and ATP. The ligation reaction is inactivated by heating the reaction to 80 degrees for 20 minutes. Finally, the amplification/detection mix contains PCR primers, TaqMan probe, dNTPs and DNA polymerase. The PCR amplification is detected in real-time with the TaqMan assay and the Ct-value reflects the amount of PDGF present in the sample. The ct-value is the threshold cycle where the PCR reaction reaches a critical

WO 01/61037

PCT/SE01/00341

13

amount of amplification product has been generated. Figure 11 shows the Ct-values for a dilution of PDGF-BB in a PBSM buffer. A high ct-value corresponds to a low, or undetectable PDGF-BB concentration.

Incubation mix : volume 14  $\mu$ L, 50mM KCl, 10 mM Tris-HCl pH 8.3, BSA 0,01%, 3 mM MgCl<sub>2</sub>, 7.5 pM probe A1c and A2c. 1  $\mu$ L of sample is added to this mix.

Ligation mix : volume 5  $\mu$ L, 50mM KCl, 10 mM Tris-HCl pH 8.3, 3 mM MgCl<sub>2</sub>, 0.8 mM ATP, 20 nM ligation template, 3 Weiss units T4 DNA ligase.

Amplification detection mix (TaqMan PCR): volume 30  $\mu$ L, 50mM KCl, 10 mM Tris-HCl pH 8.3, 0.4 mM MgCl<sub>2</sub>, 0.33 mM dNTPs, 1x buffer A, 1  $\mu$ M forward primer, 1  $\mu$ M reverse primer, 83 nM TaqMan probe, 1.56 Units AmpliTaq Gold polymerase (Perkin-Elmer).

Probe A1c :

TACTCAGGGCACTGCAAGCAATTGTGGTCCCAATGGGCTGAGTATGTGGTCTATGTCGTC  
GTTTCGCTAGTAGTTCCTGGGCTGCAC

Probe A2c :

TCGAGGCGTAGAATTCCCCCGATGCGCGCTGTTCTTACTCAGGGCACTGCAAGCAATTG  
TGGTCCCAATGGGCTGAGTAT

Splint template for ligation (6+20): GGGGGAATTCTACGCCTCGAGTGCAG

Frw primer: ATGTGGTCTATGTCGTCGTTTCG

Rew primer: TGAGTAAGAACAGCGCGCAT

Taq Man probe A1+2c: Fluor-CTGCACTCGAGGCGTAGAATTCCCC-Tamra

PCR cycles: hold 10 min 95, cycle 95 (15 sec) - 60 (1 min) 45 times

#### **Combined ligation mix and pcr mix for higher sensitivity**

The two mixes for ligation and pcr detection may be combined and added in one step. The incubation mix remains the same, with sample and reactive probes. The incubation is preferably done in a small volume and upon addition of the ligation/detection mix the volume is significantly increased, thus diluting the unbound proximity-probes and decreasing their reactivity. However, the analyte-bound proximity-probes maintain their high local concentration and high reactivity since a new equilibrium does not have time to set during the short ligation reaction.

WO 01/61037

PCT/SE01/00341

14

Figure 12 shows the result of such a combined ligation/detection variant of proximity probing with selex aptamers detecting PDGF-BB. Here, the incubation mix contained 20 pM aptamers A1c and A2c in a 10 uL volume with 1  $\mu$ L of the sample. The 40  $\mu$ L ligation and detection mix was added and left at room temperature for 5 min, before the PCR reaction was started by heating the sample and thereby simultaneously stopping the ligation reaction. The ligation/detection mix contained T4 DNA ligase, ligation template (10+10) 40 nM, ATP, TaqGold DNA polymerase, dNTP's, PCR primers, and TaqMan probe.

A five fold dilution of the unbound proximity-probes is accomplished by the volume increase when the ligation/detection mix is added. This procedure also minimises the risk of contamination since the vessel is never opened for a second addition, and the sensitivity of the analysis increases through the dilution effect.  $1 \times 10^{-19}$  moles of PDGF-BB was detected in the assay shown in figure 12. This is roughly a 500-fold increase in sensitivity over the reported sensitivity of commercial ELISAs for PDGF-BB.

**Example 2: Universal proximity-probes.**

When detecting an analyte the proximity-probes must not always bind to the analyte itself, but can instead bind via a first affinity reagent. In the case of an analyte with two binding sites, the first affinity reagents bind the analyte and the proximity-probes bind to these primary reagents (figure 13). This strategy has advantages when designing universal proximity-probes here exemplified with antibodies as target-binding moieties.

The laborious conjugation of nucleic acid sequences to various antibodies or other binding moieties can be overcome by making universal proximity-probes. These would comprise a secondary pair of binding moieties, each one capable of binding once to the Fc region (constant region) of a primary binding antibody pair. The Fc region is constant for many different antibodies of various specificities. So, the nucleic acids are conjugated to these secondary binding moieties, and used universally for the detection of many different analytes. The primary antibody pair is incubated with the analyte and the secondary reactive binding reagents are added and allowed to preferentially react when in a high local concentration (figure 13).

WO 01/61037

PCT/SE01/00341

15

**Example 3: Competitive proximity-probing for analytes with only one binding site**

It is not always the case that two binding moieties are available for an analyte. This can be overcome by using a competitive assay. Herein, a purified amount of the analyte itself is conjugated to a nucleic acid and the one existing binding moiety is conjugated with the other reactive nucleic acid. When these two conjugates are permitted to react in a sample mixture containing an unknown amount of the analyte, the non-conjugated analyte of unknown amount in the sample will compete for binding to the binding moiety of the proximity-probe thereby decreasing the probability of the conjugated nucleic acids reacting. The signal from the reaction is in this case inversely proportional to the analyte concentration.

**Example 4: Multiplex protein detection assay**

Several analytes may be simultaneously detected by using several proximity-probe pairs, each specific for their distinct analyte. These proximity-probe pairs have unique nucleic acid sequences in order to distinguish them from other pairs.

In one embodiment, the oligonucleotides all have the same PCR primer sites and the same ligation junction but unique identifier sequences. If different PCR primer sites and different ligation junctions are used, the risk of generating false PCR products due to cross reactivity will greatly increase which should be avoided. During the PCR the different amplicons representing the existence of different proteins are simultaneously amplified. These different PCR products may be detected by any of several methods, such as DNA microarrays, mass spectrometry, gel electrophoresis (different lengths of products), or other. A true positive ligation must contain both sequence identification tags form correct pairs of oligonucleotides in order to score as a true positive, figure 14. It is possible to use a DNA micro array for sorting unique amplification products corresponding to the presence of a certain protein.

**Example 5a: Screening ligand candidates in a large pool**

Ligands to for example cell surface receptors can be found by screening cDNA expression clones for affinity towards said receptor. Such screening is usually carried out in various of solid phase formats where the known receptor is immobilised.



WO 01/61037

PCT/SE01/00341

16

Proximity-probing provides an alternative means to screen large sets of ligand candidates without the need for a solid phase. One needs an antibody capable of binding to the known receptor in such a way that it blocks binding by the unknown receptor ligand. To the receptor an oligonucleotide is conjugated, that is capable of ligating to a second oligonucleotide conjugated to the antibody. To a set of sample mixtures, the receptor and antibody is added to interact with a potential receptor ligand. The ligation mix is added to the sample, and if a receptor ligand exists in the sample, ligation of the oligonucleotides will be inefficient due to the lack of nearness between them since receptor-antibody complexes fail to form in the prescence of the receptor ligand. A sample containing a potential ligand will therefore give a smaller signal. This method is not limited to receptors and their ligands, but could be used for all types of biomolecular interactions of interest.

**Example 5b: Screening drug candidates from large libraries**

In a fashion similar to the one described for the unknown ligand screening method one can also screen for drug candidates. For example a receptor and its ligand are both conjugated with oligonucleotides. In a mixture containing a competitive drug candidate the ligation between the oligonucleotides will be inhibited since receptor ligand complexes fail to form. Large drug candidate libraries can thus be screened with minimal material use of receptor and its ligand.

**Example 6: Detection of Infectious agents**

By using probes with specificity for a surface molecule of an infectious agent such as a virus or an antibody, proximity probing could be used detect such agents at very low amounts. The two probes may be designed to bind to the same target if these are abundant on the surface and clustered near each other. The two probes may also bind to two different targets on the agent but also with the need to be near each other.

**Example 7: Target analyte with more than two binding sites**

By using more than two proximity-probes per analyte a more sensitive detection can be accomplished. This assays is designed to require more than one ligation event to generate a signal. When three binding moieties can simultaneously bind the analyte,

WO 01/61037

PCT/SE01/00341

17

three different proximity-probes are made, each with different conjugated nucleic acid sequences. One with a 3' extension (A), one with a 5' extension (B), and one having both 3' and 5' extensions (C). The 3' end of A ligates to the 5' end of C and the 3' end of C ligates to the 5' end of B. In the case of PCR detection, the primers placed on A and B resulting in a PCR product spanning over the entire C probe. The C probe is preferentially constructed using a ssDNA aptamer binding moiety to facilitate the polymerisation over the nucleic acid conjugated to the C probe.

This strategy will decrease the background ligation due to the requirement of two ligation events for a false positive signal compared to one event as seen in the system with two ligatable proximity-probes. During assay optimisation, with decreasing proximity-probe concentration the likelihood of background ligation decreases as the third root of the concentration compared to the squared root with the two-probe system.

**Example 8: Using a dimerising affinity moiety**

If only one binding moiety can be constructed into a proximity-probe a multimeric affinity reagent can create proximity by dimerising the analytes, enabling their detection. This can be exemplified by an aptamer based binding moiety constructed into a proximity-probe and an antibody which dimerises the analyte.

Many selex derived aptamers bind to only one site on the protein target. Since proximity probing requires the binding of at least two probes to each target in order to enable detection, these monovalent targets will be more difficult to detect. By adding to the incubation mixture a bivalent antibody (or other affinity reagent) capable of simultaneously binding two targets this may be overcome. The antibody must bind at a site separate from the selex aptamer so a complex of five molecules may form consisting of the antibody, two target proteins, and the two ligatable selex aptamer based proximity-probes.

In the presence of target, ligation of the aptamers is promoted by their proximity provided by the dimerising antibody. This system may alternatively be used to detect and quantify the antibody itself, by using constant amounts of the target and selex aptamer.

WO 01/61037

PCT/SE01/00341

18

**Example 9: Screening for ligand-receptor interaction antagonists**

When searching for antagonists of a ligand-receptor interaction for pharmaceutical use a sensitive, specific and rapid testing system is beneficial in order to screen vast libraries of candidate compounds. This is sometimes referred to as high throughput screening.

The following is an example that shows how the PDLA detection system can be redesigned to test whether or not a compound binds a certain receptor. This screening principle is here exemplified by PDGF-BB and its receptor interaction. By adding a surplus of soluble receptor to an incubation mix of PDGF-BB and proximity-probes, the binding of the probes to pdgf is blocked by the receptor and no signal is generated. However, if a molecule which binds to the receptor in a competitive fashion is added to the incubation mix the PDGF is "liberated" and accessible to the proximiity probes generating a signal.

In order to test this principle PDGF-AA was used to mimic the action of an antagonist since it is capable of binding the pdgf-alfa receptor but not the aptamers. 6.4 pM PDGF-BB was incubated with 5 pM of aptamer based proximity-probes and 2.5 nM of soluble PDGF-alpha receptor (in surplus). Upon addition of 100 nM PDGF-AA, which binds the receptor but not the aptamers, a 3-fold increase in signal was generated from the "liberated" PDGF-BB now accessible to the proximiity-probes.

WO 01/61037

PCT/SE01/00341

19

**References:**

- 1) Hart HE, Greenwald EB, Scintillation proximity assay (SPA)--a new method of immunoassay. Direct and inhibition mode detection with human albumin and rabbit antihuman albumin., Mol Immunol 1979 Apr;16(4):265-7
- 2) Szollosi J, Damjanovich S, Matyus L, Application of fluorescence resonance energy transfer in the clinical laboratory: routine and research. Cytometry 1998 Aug 15;34(4):159-79
- 3) Ueda H, Kubota K, Wang Y, Tsumoto K, Mahoney W, Kumagai I, Nagamune T, Homogeneous noncompetitive immunoassay based on the energy transfer between fluorolabeled antibody variable domains (open sandwich fluoroimmunoassay)., Biotechniques 1999 Oct;27(4):738-42
- 4) Koo EH, Lansbury PT Jr, Kelly JW, Amyloid diseases: abnormal protein aggregation in neurodegeneration., Proc Natl Acad Sci U S A 1999 Aug 31;96(18):9989-90
- 5) Prusiner SB, McKinley MP, Bowman KA, Bolton DC, Bendheim PE, Groth DF, Glenner GG, Scrapie prions aggregate to form amyloid-like birefringent rods., Cell 1983 Dec;35(2 Pt 1):349-58
- 6) Nadeau JG, Pitner JB, Linn CP, Schram JL, Dean CH, Nycz CM, Real-Time, Sequence-Specific Detection of Nucleic Acids during Strand Displacement Amplification. Anal Biochem 1999 Dec 15;276(2):177-187
- 7) van Deursen PB, Gunther AW, van Riel CC, van der Eijnden MM, Vos HL, van Gemen B, van Strijp DA, Tackent NM, Bertina RM, A novel quantitative multiplex NASBA method: application to measuring tissue factor and CD14 mRNA levels in human monocytes. Nucleic Acids Res 1999 Sep 1;27(17):e15.
- 8) White SR, et al., Signal amplification system for DNA hybridization assays based on in vitro expression of a DNA label encoding apoaquorin., Nucleic Acids Res. 1999 Oct 1;27(19):e25.

WO 01/61037

PCT/SE01/00341

20

- 9) Kwiatkowski RW, Lyamichev V, de Arruda M, Neri B, Clinical, Genetic, and Pharmacogenetic Applications of the Invader Assay., Mol Diagn 1999 Dec;4(4):353-364
- 10) Gibson, U.E., heid, C.A., Williams, P.M. Genome Res., 6, 995-1001
- 11) Tyagi, S.Kramer, F. R. Molecular beacons: probes that fluoresce upon hybridization, Nat Biotechnol(1996), 14, 3 , 303-8
- 12) Steuerwald N, Cohen J, Herrera RJ, Brenner CA, Analysis of gene expression in single oocytes and embryos by real-time rapid cycle fluorescence monitored RT-PCR.Mol Hum Reprod 1999 Nov;5(11):1034-9
- 13) Gentalen E, Chee M , A novel method for determining linkage between DNA sequences: hybridization to paired probe arrays., Nucleic Acids Res 1999 Mar 15;27(6):1485-91
- 14) Baner J, Nilsson M, Mendel-Hartvig M, Landegren U, Signal amplification of padlock probes by rolling circle replication., Nucleic Acids Res 1998 Nov 15;26(22):5073-8
- 15) Nilsson M, Malmgren H, Samiotaki M, Kwiatkowski M, Chowdhary BP, Landegren U, Padlock probes: circularizing oligonucleotides for localized DNA detection., Science 1994 Sep 30;265(5181):2085-8
- 16) Gold, L. Polisky, B. Uhlenbeck, O. Yarus, M., Diversity of oligonucleotide functions. Annu Rev Biochem, 1995, 64, 763-97
- 17) Green, L. S. Jellinek, D. Jenison, R. Ostman, A. Heldin, C. H. Janjic, N., Inhibitory DNA ligands to platelet-derived growth factor B-chain, Biochemistry, 1996, 35, 45, 14413-24

WO 01/61037

PCT/SE01/00341

21

## CLAIMS

1. A method for detecting and/or quantifying one or more analyte(s) in solution, characterised by

- a) binding of two or more proximity probes to a respective binding site on said analyte(s), wherein the proximity probes are comprised of a binding moiety and a thereto coupled nucleic acid;
- b) allowing the binding moiety to bind to the analyte(s) and allowing the nucleic acids to interact with each other if they are in close proximity to each other; and
- c) detection and/or quantification of the degree of interaction between the nucleic acids

with the proviso that the binding moieties and the analyte(s) not all comprise nucleic acid.

2. A method according to claim 1, further comprising amplification of the interacted nucleic acids and detection/quantification of the amplification product.

3. A method according to claims 1 or 2, wherein the binding moieties of the proximity probes are selected from a protein, such as a monoclonal or polyclonal antibody, lectin, soluble cell surface receptor, combinatorially derived protein from phage display or ribosome display, peptide, carbohydrate, nucleic acid, such as an aptamer, or combinations thereof.

4. A method according to claims 1, 2 or 3, wherein the analyte(s) is/are protein(s), protein aggregate(s), prion(s) and/or nucleic acid(s).

5. A method according to claims 1, 2, 3 or 4, wherein the binding sites for the binding moieties of the proximity probes are on one and the same analyte, or on two close analytes.

WO 01/61037

PCT/SE01/00341

22

6. A method according to any of the above claims, wherein the binding moieties are antibodies and said antibodies each bind to the analyte(s) via a further antibody having binding specificity for the analyte(s), and wherein the binding moieties are directed against the Fc portion of the further antibody.

7. A method according to any of the above claims, wherein the interaction of said nucleic acids coupled to the binding moieties is through hybridisation to a common splint template and ligation of the nucleic acid ends.

8. A kit for detecting and quantifying one or more analyte(s) in solution, comprising

- a pair of proximity probes comprising binding moieties with affinity for the analyte(s) and each provided with a nucleic acid (reactive functionality) capable of interacting with each other; and optionally

- a ligase and a splint template for joining the nucleic acids,
- primers which hybridise to each of the nucleic acids.

9. A kit according to claim 8, comprising

- a first pair of binding moieties being a first pair of antibodies with affinity for the analyte; and
- a second pair of binding moieties being a second pair of antibodies directed against the Fc portion of the first pair of antibodies.

10. A kit according to claim 8, comprising three proximity probes one with a 3' free nucleic acid (A), one with a 5' free nucleic acid (B), and one with both 3' and 5' free nucleic acids (C), wherein the 3' end of A interacts with the 5' end of C and the 3' end of C interacts with the 5' end of B.

11. A kit according to claim 8, wherein the binding moieties are aptamers and further comprising a bivalent affinity reagent for dimerising two analytes each with only one aptamer binding site.

WO 01/61037

PCT/SE01/00341

23

12. A kit according to claim 8, comprising several pairs of proximity probes each with a specific binding moiety and unique nucleic acids for identification.

13. Use of the method according to any one of claims 1-7 and/or the kit according to any one of the claims 8-12 for screening for ligand-receptor interaction antagonists a high throughput screening procedure.

14. Use of the method according to any one of claims 1-7 and/or the kit according to any one of the claims 8-12 for competitive detection and/or quantification of an unknown analyte in solution.

15. Use of the method according to any one of claims 1-7 and/or the kit according to any one of the claims 8-12 for screening ligand candidates in a large pool.

16. Use of the method according to any one of claims 1-7 and/or the kit according to any one of the claims 8-12 for screening of drug candidates from large libraries.

17. Use of the method according to any one of claims 1-7 and/or the kit according to any one of the claims 8-12 for detection of infectious agents.

18. Use according to claim 17, wherein the infectious agent is detected in food for humans and animals.




WO 01/61037

PCT/SE01/00341

1/6






Figure 1. Definition of symbols



WO 01/61037

PCT/SE01/00341

2/6

**Figure 2.** Template promoted ligation variants**Figure 3.** Fill-in polymerisation prior to ligation**Figure 4.** Ligation of supplementary oligonucleotides, x and y, to the proximity-probe-hybridisation oligonucleotide z. Amplification primer sites a and b.**Figure 5.** Generation of circular DNA, for rolling circle amplification**Figure 6.** Priming of rolling circle amplification by a proximal oligonucleotide

WO 01/61037

PCT/SE01/00341

3/6

Figure 7. Template unassisted ligation by T4 RNA ligase




Figure 8. Both probes with free 3'- ends capable of hybridising to each other.





Figure 9. Requirement of two ligation events, using three binding moieties. Amplification primer sites a and b.



**PCT/SE01/00341**

**FIGURE 10**



WO 01/61037

PCT/SE01/00341

5/6

FIGURE 11





FIGURE 12



WO 01/61037

PCT/SE01/00341

6/6




FIGURE 13




FIGURE 14

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/00341

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C12Q 1/68, G01N 33/536

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C12Q, C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI, BIOSIS, MEDLINE, IEL, ELSEVIER

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9700446 A1 (LANDGREN, ULF), 3 January 1997 (03.01.97), figure 1, abstract --	1-18
A	WO 9306240 A1 (CYTOCELL LIMITED), 1 April 1993 (01.04.93), page 4, line 21 - line 31; page 6, line 5 - line 18, figure 1 --	1-18
A	EP 0320308 A2 (BIOTECHNICA INTERNATIONAL, INC.), 14 June 1989 (14.06.89), column 1, line 46 - column 2, line 31; column 3, line 3 - line 13, figure 1 --	1-18

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

\* Special categories of cited documents

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

15 June 2001

Date of mailing of the international search report

19 -06- 2001

Name and mailing address of the ISA:

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

FRIDA PLYM FORSHELL/EE

Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/00341

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0185494 A2 (APPLIED BIOSYSTEMS, INC.), 25 June 1986 (25.06.86), abstract  --	1-18
A	US 5846709 A (DAVID SEGEV), 8 December 1998 (08.12.98), abstract  --	1-18
E,A	WO 0123894 A1 (EVOTEC BIOSYSTEMS AG), 5 April 2001 (05.04.01), abstract  -- -----	4,18



**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

28/05/01

International application No.

PCT/SE 01/00341

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	9700446	A1	03/01/97	AU	702125 B	11/02/99
				AU	6143996 A	15/01/97
				CA	2224674 A	03/01/97
				EP	0832431 A	01/04/98
				JP	11508040 T	13/07/99
				SE	504798 C	28/04/97
				SE	9502196 A	17/12/96
WO	9306240	A1	01/04/93	AT	152778 T	15/05/97
				AU	672367 B	03/10/96
				AU	2558692 A	27/04/93
				CA	2118913 A	01/04/93
				DE	69219627 D,T	04/09/97
				DK	666927 T	15/09/97
				EP	0666927 A,B	16/08/95
				SE	0666927 T3	
				ES	2101116 T	01/07/97
				JP	6510669 T	01/12/94
EP	0320308	A2	14/06/89	SE	0320308 T3	
				AT	96848 T	15/11/93
				AU	622426 B	09/04/92
				AU	2675588 A	15/06/89
				BR	8806539 A	22/08/89
				CA	1323293 A	19/10/93
				CN	1035133 A	30/08/89
				DE	3885422 D,T	28/04/94
				ES	2061694 T	16/12/94
				JP	1905966 C	24/02/95
				JP	2002934 A	08/01/90
				JP	6034759 B	11/05/94
EP	0185494	A2	25/06/86	SE	0185494 T3	
				DE	3586090 A	25/06/92
				JP	1919077 C	07/04/95
				JP	6044880 B	15/06/94
				JP	61191964 A	26/08/86
				US	4883750 A	28/11/89
				US	5242794 A	07/09/93
				US	5521065 A	28/05/96
				US	5962223 A	05/10/99
US	5846709	A	08/12/98	AU	7207294 A	03/01/95
				CA	2163897 A	22/12/94
				EP	0702729 A	27/03/96
				JP	9500525 T	21/01/97
				WO	9429485 A	22/12/94
WO	0123894	A1	05/04/01	NONE		

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**